Medical Condition News

RSS

Eritoran well tolerated in Phase II trial for severe sepsis

The investigational compound, eritoran tetrasodium ("eritoran," also known as E5564) appeared to be well tolerated in patients with severe sepsis in a Phase II trial published in the January issue of Critical Care Medicine, the official journal of the Society of Critical Care Medicine, the largest multiprofessional organization dedicated to ensuring excellence and consistency in the practice of critical care.

22 Dec 2009

Declining use of Advair for COPD, Spiriva patient share increasing

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.

22 Dec 2009

Newly identified targets in treating inflammatory disorders of the gastrointestinal tract

Digestive-disease-associated mortality accounts for a major part of all deaths in Western societies and inflammatory diseases such as GI infections, viral hepatitis, GERD or cancers due to chronic inflammation have a tangible economic and social impact.

22 Dec 2009

GI Dynamics' EndoBarrier non-surgical type 2 diabetes therapy receives European CE mark approval

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier™, a non-surgical therapy to treat type 2 diabetes and obesity. The CE marking (an acronym for the French "Conformite Europeenne") certifies that a product has met EU requirements for marketing in Europe. Clinical trials involving more than 270 patients have demonstrated the significant weight loss and diabetes improvement achieved with the EndoBarrier Gastrointestinal Liner.

22 Dec 2009

Four Latin American cancer patients receive treatment using RapidArc radiotherapy technology

Four cancer patients became the first in Latin America to receive treatment using a fast form of image-guided radiotherapy that potentially enables doctors to improve outcomes while extending modern care to more patients. Doctors at Hope International Centro de Radioterapia of Guatemala are now treating four patients using RapidArc® radiotherapy technology from Varian Medical Systems, one with recurring prostate cancer, one with a nasal cavity tumor, one with rectal cancer, and one with recurring glioblastoma multiforme--an aggressive type of brain tumor.

22 Dec 2009

Arena Pharmaceuticals submits lorcaserin NDA to the FDA

Arena Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss. The submission is based on an extensive data package from lorcaserin's clinical development program that includes 18 clinical trials totaling 8,576 patients.

22 Dec 2009

Chordoma surgery through the nose

A remarkable brain surgery at Saint John’s Health Center has restored vision to a seriously ill young woman from Spain—and the entire operation was performed through her nose without an incision.

22 Dec 2009

QLT Ophthalmics to distribute Visudyne in the U.S. market

QLT Inc. ("QLT" or the "Company") is pleased to announce the establishment of its commercial presence in the United States through a newly formed U.S. subsidiary, QLT Ophthalmics, Inc. ("QOI"). QOI will take on the sales and marketing of Visudyne(R) in the U.S.

22 Dec 2009

Shire submits REPLAGAL BLA with the FDA

Shire plc , the global specialty biopharmaceutical company, today announced that it has submitted a BLA with the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease. REPLAGAL first received marketing authorization in the European Union in 2001, and is approved for the treatment of Fabry disease in 45 countries.

22 Dec 2009

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

ProActive Capital Resources Group, a company dedicated to the discovery and creation of value in the small and micro-cap marketplace, is proud to announce client presentations at the 3rd Annual OneMedForum held in San Francisco, January 12-13, 2010. ProActive clients presenting are: Access Pharmaceuticals, ImmunoCellular Therapeutics, DataTrak International, Quantum Immunologics, with Protox Therapeutic's presentation pending.

22 Dec 2009

Health and education leaders commend school for promoting physical activity among students

During a visit today to Conrad Weiser Middle School, Department of Health Secretary Everette James and Secretary of Education Gerald Zahorchak commended the school for its efforts to increase physical activity among students.

22 Dec 2009

Orthopaedic Center of the Rockies updates its name to Orthopaedic & Spine Center of the Rockies

The Orthopaedic Center of the Rockies (Fort Collins and Loveland, CO) has updated its name to Orthopaedic & Spine Center of the Rockies. The name change highlights the 40-year-old medical practice's services for patients with disorders or injuries to their back or neck.

22 Dec 2009

CPRIT extends Company Investment application date to January 12, 2010

The Cancer Prevention and Research Institute of Texas (CPRIT) announced today that it has extended the deadline to January 12, 2010 to file a letter of intent to submit a proposal for the Company Investment request for application (RFA). The RFA is available on the CPRIT website, www.cprit.state.tx.us/funding.html.

22 Dec 2009

ADHD Support Twitter page from Shire

Shire plc, the global specialty biopharmaceutical company, announced the launch of its newest online Attention-Deficit/Hyperactivity Disorder (ADHD) resource, the ADHD Support Twitter(TM) page (http://twitter.com/adhdsupport), derived from the Shire award-winning online educational resource, ADHDSupport.com.

22 Dec 2009

Health experts offer recommendation to improve school meal programs

More fruits, vegetables, and whole grains, less sodium and a limit on calories served per meal—those are just some of the recommendations a committee of experts has made on how to improve the nation’s school lunch and breakfast menus.

22 Dec 2009

AADA lauds indoor tanning tax in the health system reform legislation

The American Academy of Dermatology Association (AADA) applauds the decision of the U.S. Senate to substitute a 10 percent federal excise tax on indoor tanning services for the proposed tax on cosmetic procedures in the Senate's health system reform legislation (H.R. 3590, the Patient Protection and Affordability Act of 2009). The indoor tanning tax, as proposed to Senate leadership by the AADA, furthers its goal of promoting wellness and prevention, and removes the harmful unintended consequences associated with a tax on cosmetic surgery procedures.

22 Dec 2009

Emisphere's oral salmon calcitonin product addresses persistent musculoskeletal pain

Emisphere Technologies, Inc. today announced a meta-analysis published in the December 2009 edition of Rheumatology Reports examining independent evidence of the analgesic action of the hormone calcitonin. This publication restates the potential of calcitonin in filling a significant unmet need for alternative treatments for persistent musculoskeletal pain.

22 Dec 2009

ZEGERID OTC approval triggers $20M milestone payment to Santarus

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has received the $20 million milestone payment previously announced on December 1, 2009 relating to the approval of ZEGERID OTC™ (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) under its over-the-counter (OTC) licensing agreement with Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc. Schering-Plough and Merck merged on November 3, 2009.

22 Dec 2009

New data shows more number of women are attending breast screening program

The number of women attending breast screening has risen, with nearly two million accepting invitations from the NHS Breast Screening Programme in 2007/08, new figures show.

22 Dec 2009

Persistent disparities exist in melanoma diagnosis

White and Hispanic individuals are being diagnosed with melanoma more frequently in recent years, whereas Hispanic and black patients continue to have advanced skin cancer at diagnosis, according to a report in the December issue of Archives of Dermatology, one of the JAMA/Archives journals.

22 Dec 2009